- Home
- AEF vs AVTX Comparison
AEF vs AVTX Comparison
Compare AEF & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AEF | AVTX |
|---|---|---|
| Founded | 1989 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 277.7M | 248.3M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | AEF | AVTX |
|---|---|---|
| Price | $7.10 | $18.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $32.29 |
| AVG Volume (30 Days) | 92.5K | ★ 345.3K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 7.13% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.57 | N/A |
| Revenue | N/A | ★ $192,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.86 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.40 | $3.39 |
| 52 Week High | $5.53 | $20.72 |
Technical Indicators
Market Signals| Indicator | AEF | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 65.52 | 51.56 |
| Support Level | $6.87 | $18.21 |
| Resistance Level | $7.00 | $19.97 |
| Average True Range (ATR) | 0.13 | 1.47 |
| MACD | 0.01 | -0.12 |
| Stochastic Oscillator | 96.59 | 35.08 |
Price Performance
Historical ComparisonAbout AEF abrdn Emerging Markets Equity Income Fund Inc.
ABERDEEN EMERGING MARKETS EQUITY INCOME FUND, INC. is a closed-end investment company. The Fund's investment objective is to seek to provide both current income and long-term capital appreciation. The Fund invests in a range of sectors, including financials, consumer staples, utilities, consumer discretionary, materials, energy, information technology, private equity, communication services, healthcare, real estate, and industrials.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).